engage checkpoint medical linkedin twitter

Advanced PET Imaging in Prostate Cancer

Advanced PET Imaging in Prostate Cancer

Dr Phillip Koo

Dr. Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer
Portrait of Phillip Koo
Dr Phillip Koo

Nuclear Medicine Physician

Banner MD Anderson Cancer Center

United States (US)

preview next

time | open 5 min | 2018

download resources

I agree that this educational programme:

Introducing the RADAR studies

Dr. Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer. He covers when to use these tools by examining the published data, specifically the RADAR 1 and 3 studies. The RADAR (radiographic assessments for detection of advanced recurrence) group, are a team of experts, including Dr Koo, who have published articles pertinent to prostate cancer imaging. The initial paper of RADAR 1 reviewed imaging guidelines with associated clinical validation studies for metastatic prostate cancer. It provided recommendations for clinical practice to improve early detection of metastatic disease. RADAR III focuses on updates regarding next generation imaging for improved guidance.

Important findings for imaging metastatic prostate cancer

In this video and associated slides, Dr Koo details the RADAR 1 and 3 recommendations, comparing conventional imaging to advanced PET imaging for detection of metastatic disease in prostate cancer. Prostate cancer PET detection rates as a function of PSA in patients with biochemical recurrence are addressed. The suitability of radiotracers for next generation imaging is discussed, and how to approach different patient groups. Lastly, what test to use based on availability, accounting for location and coverage by MEDICARE. View the video and slides provided as part of our educational resources and practical guidance for medical oncologists and urologists.

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Other programmes of interest

preview next